Over 12,000 Pharmaceutical and Biopharmaceutical Manufacturing Professionals gathered at Interphex, which took place at the Jacob Javits Center in New York City from March 17-19. During the three-day event, industry professionals, representing 19 different countries, had the chance to see products and equipment from over 900 life science manufacturers, suppliers and service providers.
The show was co-located with Biotechnica and The PharmaMedDevice Symposium.
Highlights of the event included keynote addresses and other sessions concerning the current and future state of the industry. The opening keynote address was presented by Steven Burrill, CEO, Burrill & Company on "The Future of Pharmaceutical and Biopharmaceutical Manufacturing". His presentation was followed by a panel discussion with senior executives from Genentech, Eli Lilly & Co. and Wyeth Pharmaceuticals about how they are handling the major concerns affecting their organizations and what they envision for the future of pharmaceutical manufacturing.
A luncheon presentation on Single Use Technology co-sponsored by BioProcessing International and BioProcess Systems Alliance titled, "Single-Use Strategies in Bioprocessing: Reducing Cost, Time and Risk," featured a panel of users and suppliers.
Exhibitors included MG America, IMA North America, Thomas Engineering, Korsch America, Getinge, Bosch Packaging, Millipore, DSM Pharmaceuticals, GE Healthcare, Pall Life Sciences, Siemens Energy & Automation Advantapure, AES Clean Technologies and Saint Gobain.
Greg Boyer, Marketing Manager, Hosokawa Micron Powder Systems said, "Our objective is to inform the Asian markets about products that our representative offices over there do not carry - for example our Micron air jet sieve. This product is less expensive compared to what our competitors offer, and is usually considered to be more accurate. We expect strong demand to come from China."
According to John Turk, director, Lifesciences, Rovisys, "This is our seventh Interphex show in the US. We were also at the Singapore edition last year, which was also our first time exhibiting there. We see the country as a hub where there are already a number of pharmaceuticals companies there. We are also looking at its neighboring countries such as Malaysia and Vietnam for further expanding our activities. India is another country where there is a boom in manufacturing and we're performing studies on how much it would cost for companies to enter the market,"
"We need to differentiate the various markets in Asia. For example, Japan's market is different from that of Korea's of China's. So the challenge for us is in how to market ourselves in these markets. In China and India, the challenge is complying with US FDA regulations. Our Manufacturing Execution Systems (MES) systems are helping companies in these countries to document their processes and track deviations, etc .. to fulfill the regulatory requirements," says Christian Woelbeling, director of marketing & sales, Werum.
The current trend is that Asian companies are looking for suppliers of turnkey solutions. For example, suppliers that can provide the full range of services such as validation, piping, storage and commissioning. Our markets are found in Phillippines, Malaysia, Indonesia. Singapore is the headquarters for our engineering activities, Johann Bonnet, market manager, Veolia Water.
Attendees included BMS, Genentech, Genzyme, ImClone, Johnson & Johnson, MassBiologics, Medimmune, Merck, Novartis, Pfizer, Purdue Pharma, Sanofi Pasteur, Schering-Plough, Teva and Wyeth.
Share this: 
Del.icio.us |
